Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Rheumatoid arthritis Primer — behind the scenes

Comprehensive review articles written by international experts are important to provide readers from diverse backgrounds with an expanding knowledge base.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Smolen, J. S. et al. Rheumatoid arthritis. Nat. Rev. Dis. Primers 4, 18001 (2018).

    Article  Google Scholar 

  2. 2.

    Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2019-216655 (2020).

    Article  PubMed  Google Scholar 

  3. 3.

    Lund Hetland, M. et al. A multicenter randomized study in early rheumatoid arthritis to compare active conventional therapy versus three biological treatments: 24 week efficacy and safety results of the NORD-STAR Trial [abstract L09]. Arthritis Rheumatol. 71 (Suppl. 10), 5237–5240 (2019).

    Google Scholar 

  4. 4.

    Croft, A. P. et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570, 246–251 (2019).

    CAS  Article  Google Scholar 

  5. 5.

    Aletaha, D. & Smolen, J. S. Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. Nat. Rev. Rheumatol. 15, 633–634 (2019).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Josef S. Smolen.

Ethics declarations

Competing interests

J.S. receives research grants from Abbvie, AstraZeneca, Lilly, Merck Sharpe & Dohme, Pfizer and Roche; and honoraria for expert advice for or symposia speaking engagements with AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, ILTOO Pharma, Janssen, Lilly, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi and UCB.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Smolen, J.S. Rheumatoid arthritis Primer — behind the scenes. Nat Rev Dis Primers 6, 32 (2020). https://doi.org/10.1038/s41572-020-0168-y

Download citation

Further reading

Search

Quick links